Vaccines make Green Cross No. 4 drugmaker

Published: 2010-08-04 07:00:00

Updated: 2010-08-04 07:00:00

Green Cross became the fourth-biggest drug manufacturer in Korea in terms of quarterly revenue, as the outbreak of Influenza A boosted overseas demand for seasonal flu vaccines.

Green Cross posted revenues of 160 billion won in the second quarter, while Dong-A Pharmaceutical topped sales with...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK